Last update Dec. 4, 2020
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Mirabegron in other languages or writings:
Mirabegron belongs to this group or family:
Main tradenames from several countries containing Mirabegron in its composition:
|Oral Bioavail.||29 - 35||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a beta3-adrenergic receptor agonist, used in overactive bladder (OAB) syndrome, to treat symptoms of urgency and increased frequency of urination, as well as incontinence.
It is administered orally once a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (EMA 2017) makes it difficult to predict transfer into breastmilk, since while the low molecular weight, the pKa and the very long half-life would facilitate transfer, the very high volume of distribution would hinder it.
On the other hand, its low bioavailability implies minimal transfer into infant plasma, except in the neonatal period and in cases of prematurity when intestinal absorption may be increased.
Until there is more published data on this drug in relation to breastfeeding, known safer alternatives during the neonatal period and in the event of prematurity may be preferable.